Publications in collaboration with researchers from Fundación Jiménez Díaz (8)

2025

  1. A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS

    British Journal of Haematology, Vol. 207, Núm. 2, pp. 624-630

  2. Generation and GMP scale-up of human CAR-T cells using non-viral Sleeping Beauty transposons for B cell malignances

    Molecular Therapy Methods and Clinical Development, Vol. 33, Núm. 1

  3. Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

    Leukemia, Vol. 39, Núm. 11, pp. 2686-2696

  4. Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndrome

    Leukemia Research, Vol. 156

  5. Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study

    Cancer, Vol. 131, Núm. 1

2024

  1. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

    Clinical and Translational Science, Vol. 17, Núm. 3

2023

  1. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes

    Leukemia Research, Vol. 134

2021

  1. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

    Leukemia, Vol. 35, Núm. 12, pp. 3542-3550